Press Releases from Imanova (3 total)
The power of combining DREADD and PET imaging technologies to be presented for t …
DREADD (Designer Receptors Exclusively Activated by Designer Drugs) technology is an exciting chemogenetic tool allowing the hijacking of neurons by a molecular switch to remotely activate or silence them.
DREADD are engineered G-protein coupled receptors that can be injected into discrete brain nuclei. Once expressed, the mutated receptors are only activated by inert drug-like small molecules injected peripherally.
In collaboration with Dr Ilse Pienner and Prof David Dexter (Imperial College London), Imanova…
Further Growth in Imanova’s Preclinical Biology Offering
Imanova is pleased to announce further expansion of its preclinical team, with the addition of new roles in both Chemistry and Biology. These new roles bring additional capacity and a broadening of capabilities to Imanova’s leading preclinical imaging offering.
Imanova provides preclinical services, both in vitro, in vivo and ex vivo, to support early stage drug development through the examination of the three pillars of drug development:
- Does the drug candidate…
Imanova plays central role in world’s most in-depth study to detect Alzheimerâ …
London, August 2016: A new multimillion-pound study, which will see the most thorough and rigorous series of tests to detect Alzheimer’s disease ever performed on volunteers, is announced today. The Deep and Frequent Phenotyping study is funded by the National Institute of Health Research (NIHR) and the Medical Research Council (MRC) and hopes to dramatically improve the success rate of clinical trials for treatments in Alzheimer’s disease.
This landmark £6.9m…
